Mitochondria-Homing HDAC3 Inhibitor Curbs Weight Gain and Fat Buildup in Obese Mice
- Attaching a TPP group to a classic HDAC pharmacophore steers HDAC3 inhibitors into mitochondria, where obesity-linked dysfunction disrupts fat burning.
- Structure-guided optimization yielded H18, a potent HDAC3 blocker that accumulates preferentially in mitochondria.
- In 3T3-L1 adipocytes, H18 limited lipid buildup, restored ATP and lowered oxidative stress.
- In diet-induced obese mice it cut weight gain and improved glucose handling, outperforming BG45.
💡 Points Based on the abstract
Before I believed the phenotype is HDAC3 inhibition in mitochondria, I'd want a non-TPP analog and a TPP-linked inactive control: cationic TPP conjugates can themselves depolarize membranes and perturb respiration, which could mimic the ATP and oxidative-stress benefits. Also check isoform selectivity (HDAC1/2) and whether mitochondrial HDAC3 is the real target, plus tolerability and clearance of a lipophilic cation in chronic dosing.
📄 Paper · Journal of Medicinal Chemistry (ACS) ↗ Design and Synthesis of Novel Mitochondria-Targeted HDAC3 Inhibitors for the Treatment of Obesity